![Patrick Kleyn](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Patrick Kleyn is the founder of Ligon Discovery, Inc. which was founded in 2007.
He holds the title of President & Chief Scientific Officer at Ligon Discovery, Inc. Dr. Kleyn's current job is Chief Scientific Officer at Gemini Genomics Plc.
Dr. Kleyn's former job was Director-Scientific Planning at The Broad Institute, Inc.
Patrick Kleyn active positions
Companies | Position | Start |
---|---|---|
Ligon Discovery, Inc.
![]() Ligon Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Ligon Discovery's primary technology platform, Small-Molecule Microarrays (SMMs), fundamentally transforms drug discovery by bringing the power of microarrays to target screening. SMMs, developed at Harvard University and the Broad Institute, use a proprietary surface chemistry to attach unmodified chemical collections to a solid surface, enabling massively-parallel screening against protein targets of any function. The scale and scope of SMMs permit a paradigmatic change in drug discovery strategy as entire protein families, molecular pathways, and even genome-wide target sets can be screened in parallel to rapidly identify small molecules with optimal characteristics for drug development. Ligon is applying SMM technology to challenging, novel targets aimed at discovery of first-in-class drugs for oncology and other selected diseases. Ligon Discovery's SMM platform is available for drug discovery collaborations. | Founder | 2009-11-05 |
Gemini Genomics Plc
![]() Gemini Genomics Plc Miscellaneous Commercial ServicesCommercial Services Part of Laboratory Corp. of America Holdings, Gemini Genomics Plc is a British company that provides clinical genomics services. The company is based in Cambridge, UK. The company was founded by Michael Edward Fitzgerald, Paul James Kelly. | Chief Tech/Sci/R&D Officer | 2009-11-05 |
Former positions of Patrick Kleyn
Companies | Position | End |
---|---|---|
The Broad Institute, Inc.
![]() The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Ligon Discovery, Inc.
![]() Ligon Discovery, Inc. Miscellaneous Commercial ServicesCommercial Services Ligon Discovery's primary technology platform, Small-Molecule Microarrays (SMMs), fundamentally transforms drug discovery by bringing the power of microarrays to target screening. SMMs, developed at Harvard University and the Broad Institute, use a proprietary surface chemistry to attach unmodified chemical collections to a solid surface, enabling massively-parallel screening against protein targets of any function. The scale and scope of SMMs permit a paradigmatic change in drug discovery strategy as entire protein families, molecular pathways, and even genome-wide target sets can be screened in parallel to rapidly identify small molecules with optimal characteristics for drug development. Ligon is applying SMM technology to challenging, novel targets aimed at discovery of first-in-class drugs for oncology and other selected diseases. Ligon Discovery's SMM platform is available for drug discovery collaborations. | Commercial Services |
Gemini Genomics Plc
![]() Gemini Genomics Plc Miscellaneous Commercial ServicesCommercial Services Part of Laboratory Corp. of America Holdings, Gemini Genomics Plc is a British company that provides clinical genomics services. The company is based in Cambridge, UK. The company was founded by Michael Edward Fitzgerald, Paul James Kelly. | Commercial Services |
The Broad Institute, Inc.
![]() The Broad Institute, Inc. BiotechnologyHealth Technology The Broad Institute, Inc. engages in the provision of research and development in biomedicals to cure infectious disease. Its scientific areas include chemical biology and therapeutics, genome regulation, cellular circuity and epigenomics, medical and population genetics, and metabolism. The company was founded by Eric S. Lander, Eli Broad and Edythe Broad in 2003 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Patrick Kleyn